Metformin versus SGLT-2 inhibitors: how low can we go?

Animals Female Humans Male Rats Canagliflozin / adverse effects Hypoglycemic Agents / adverse effects Metformin / pharmacology Renal Insufficiency, Chronic / chemically induced Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
05 2022
Historique:
received: 14 02 2022
revised: 21 02 2022
accepted: 22 02 2022
entrez: 24 4 2022
pubmed: 25 4 2022
medline: 27 4 2022
Statut: ppublish

Résumé

The progression of chronic kidney disease is difficult to stop once established. Metformin and sodium-glucose cotransporter 2 inhibitors show promise, but clinical trials with a head-to-head comparison in patients with more advanced (stage 3b-4) chronic kidney disease are largely lacking, partly for safety reasons. In this issue, Corremans et al. compare the effects of metformin and canagliflozin in rats with adenine-induced moderate (stage 2-4) chronic kidney disease. Metformin halted progression, whereas canagliflozin did not. This commentary puts the results in a wider clinical context.

Identifiants

DOI: 10.1016/j.kint.2022.02.012 PMID: 35461613
pubmed: 35461613
pii: S0085-2538(22)00169-7
doi: 10.1016/j.kint.2022.02.012
pii:
doi:

Substances chimiques

Canagliflozin 0SAC974Z85
Hypoglycemic Agents 0
Metformin 9100L32L2N
Sodium-Glucose Transporter 2 Inhibitors 0

Types de publication

Journal Article Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

874-877

Commentaires et corrections

Type : CommentOn

Informations de copyright

Copyright © 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Auteurs

Menno Pruijm (M)

Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Department of Medicine, Lausanne, Switzerland. Electronic address: menno.pruijm@chuv.ch.

Olivier Phan (O)

Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Department of Medicine, Lausanne, Switzerland.

Anne Zanchi (A)

Service of Nephrology and Hypertension, Lausanne University Hospital and University of Lausanne, Department of Medicine, Lausanne, Switzerland; Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › Glucides › Hétérosides › Glucosides › Canagliflozine › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › Composés chimiques organiques › Amidines › Guanidines › Biguanides › Metformine › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Insuffisance rénale chronique › Metformin versus SGLT-2 inhibitors: how low can we go?
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › Inhibiteurs du cotransporteur sodium-glucose de type 2 › Metformin versus SGLT-2 inhibitors: how low can we go?